MAPT and Alzheimer disease: Thus, our results showed that the double‐phosphorylated tau tryptic peptide p‐tau(231+235), but not the mono‐phosphorylated p‐tau231, is highly and specifically increased in brains of patients with AD at Braak stages V/VI.